This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Forward Step By Step With Action Plan 2016 - Continued Revenue Growth - Significant Pipeline Progress

3. Guidance 2013

In 2013, total Group revenues are expected to grow to a level between € 90 m to € 100 m. This assumption is based on the current order book, expected new contracts and contract extensions and most importantly on the achievement of certain milestone payments.

Evotec expects research and development (R&D) expenses in 2013 to increase above the levels of 2012. This is primarily due to additional investments in the strategic Cure X franchise primarily in the fields of metabolic diseases and regenerative medicine. In total, R&D expenditure is expected to be around € 10 m in 2013.

On that basis Evotec's Group operating result before impairment and changes in contingent consideration, if any, for the year 2013 is expected to improve over 2012. The Company expects to maintain its liquidity above € 60 m at the end of 2013, excluding any potential cash outflow for M&A transactions and related payments.

Webcast / Conference Call

Evotec will broadcast its press & analyst conference in Frankfurt live on the internet. The Management Board will inform you about the FY 2012 results as well as update you on the status of "Action Plan 2016 – Innovation Efficiency in Drug Discovery" and present an outlook for the fiscal year 2013.
Date: Tuesday, 26 March 2013
Time: 9.00 am CET (08.00 am GMT/04.00 am EDT) 

To join the audio webcast and to access the presentation slides you will find a link on our home page shortly before the event. For those who prefer to listen to the presentation via phone, please dial:
From Germany: +49 (0)69 20 17 44 210
From UK:  +44 207 153 9154
From USA: +1 877 423 0830
Access Code: 638618#

The on-demand version of the webcast will be available on our website: > Investors > Events > Financial Calendar.


Evotec is a drug discovery alliance and development partnership company focused on rapidly progressing innovative product approaches with leading pharmaceutical and biotechnology companies. We operate worldwide providing the highest quality stand-alone and integrated drug discovery solutions, covering all activities from target-to-clinic. The Company has established a unique position by assembling top-class scientific experts and integrating state-of-the-art technologies as well as substantial experience and expertise in key therapeutic areas including neuroscience, pain, metabolic diseases as well as oncology and inflammation. Evotec has long-term discovery alliances with partners including Bayer, Boehringer Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca and Ono Pharmaceutical. In addition, the Company has existing development partnerships and product candidates both in clinical and pre-clinical development. These include partnerships with Boehringer Ingelheim, MedImmune and Andromeda (Teva) in the field of diabetes, and with Roche in the field of Alzheimer's disease. For additional information please go to .

FORWARD LOOKING STATEMENTS — Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this report. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.
Fiscal Year 2012 Results
Key figures of consolidated income statement
Evotec AG and subsidiaries
In T€ except share data and per share data
  January to December  
  2012 2011 Change in %
Revenues 87,265 80,128 9
Gross margin in % 35.6 43.7  
Research and development expenses (8,340) (8,437) -1
Selling, general and administrative expenses (16,301) (15,760) 3
Amortisation of intangible assets (2,768) (1,703) 63
Impairment of intangible assets (3,505) (2,058) 70
Reversal of impairment of intangible assets -- 1,501 -100
Other operating income 2,202 1,426 54
Other operating expenses (5,513) (4,747) 16
Operating income (expense) (3,202) 5,207 -161
Operating income* 1,401 5,764 -76
Net income 2,478 6,651 -63
Weighted average shares outstanding 117,295,847 116,022,213  
Net income per share (basic and diluted) 0.02 0.06 -66
* Excluding impairments and reversal of impairments and changes in contingent considerations
Key figures of consolidated statement of financial position
Evotec AG and subsidiaries        
In T€
  31 Dec 2012 31 Dec 2011 Change in %
Cash, cash equivalents and investments 64,159 62,428 3
Working capital 3,287 (11,157) -71
Current and non-current loans and finance lease obligations 17,402 15,566 12
Stockholders' equity 152,547 147,245 4
Total assets 225,427 218,213 3
CONTACT: Dr. Werner Lanthaler
         Chief Executive Officer
         +49.(0)40.560 81-242
         +49.(0)40.560 81-333 Fax

         Evotec AG 
         Manfred Eigen Campus
         Essener Bogen 7
         22419 Hamburg (Germany)

         Gabriele Hansen
         Head of Corporate Communications
         +49.(0)40.560 81-255
         +49.(0)40.560 81-222 Fax

         Evotec AG 
         Manfred Eigen Campus
         Essener Bogen 7
         22419 Hamburg (Germany)

6 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.18 0.00%
FB $117.43 0.00%
GOOG $692.36 0.00%
TSLA $232.32 0.00%
YHOO $36.01 0.00%


Chart of I:DJI
DOW 17,750.91 -140.25 -0.78%
S&P 500 2,063.37 -18.06 -0.87%
NASDAQ 4,763.2240 -54.37 -1.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs